Nonalcoholic fatty liver disease (NAFLD) is no longer considered to be a normal physiologic condition without any clinical significance. It is now widely accepted that nonalcoholic steatohepatitis (NASH), a type of fatty liver disease, can progress to end-stage liver disease and increase the risk of mortality. In addition, NAFLD patients are associated with a significantly higher overall mortality as well as liver-related mortality compared to the age-and gender-adjusted general population. It is generally accepted that liver-related mortality does not increase in patients with simple steatosis. We do not and probably cannot conclusively determine if this is actually the case in near future since liver biopsy is still the only test that can differentiate NASH from simple steatosis. The incidence of NASH was reported to be 2.2% among Korean living liver donors among whom the overall incidence of NAFLD was 51.4%. 8 Therefore, the prevalence of NASH among individuals with NAFLD is estimated to be 4.3%.
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Since this study included patients with ALT level elevated up to 120 IU/L, the proportion of NASH cases may be different Furthermore, in the study by Oh et al, 7 serum ALT or GGT level was used to predict the presence of pre-existing metabolic syndrome, but their usefulness in predicting the development of metabolic syndrome or mortality is unknown. Therefore, it is still unclear whether the use of serum ALT or GGT levels within the upper fourth quartile of the conventional normal range is in fact helpful for detecting metabolic syndrome or predicting mortality in ordinary clinical practice.
Thirdly, it is still unknown whether the increase in liver-related deaths in Korean people with slightly higher aminotransferase activity that still within the normal range can be attributed to NAFLD or other liver diseases including autoimmune hepatitis or Wilson's disease. 6 In the study by
Kim et al, 6 serum HBsAg and/or anti-HCV antibody levels
were not tested, and the presence of underlying liver cirrhosis was excluded only by a self-report questionnaire.
History of alcohol abuse was also obtained only by the self-report questionnaire. Therefore, it is still unknown whether the increased number of liver-related deaths was caused by 
